Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.50 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173918 | 0.76 | KIT (0.55) | AKT1PKMHSD17B10MEN1KMT2A | |
| SCHEMBL12174039 | 0.76 | P2RY1 (0.57) | AKT1PKMHSD17B10ATMMEN1 | |
| Sulfaethidole SCHEMBL152872 | 0.76 | AKT1 (1.00) | AKT1PKMHSD17B10ATMMEN1 | |
| SCHEMBL26786572 | 0.75 | EGFR (1.00) | EGFRAURKBTTBK1TTBK2 | |
| SCHEMBL5409859 | 0.75 | PKM (0.65) | AKT1PKMHSD17B10ATMMEN1 | |
| Sulfaethidole SCHEMBL10510090 | 0.75 | AKT1 (0.97) | AKT1PKMHSD17B10ATMMEN1 | |
| Sulfaethidole SCHEMBL1651230 | 0.74 | AKT1 (0.95) | AKT1PKMHSD17B10ATMMEN1 | |
| SCHEMBL2252773 | 0.73 | TTBK1 (0.66) | EGFRAURKBTTBK1TTBK2 | |
| SCHEMBL11893076 | 0.72 | AKT1 (0.77) | AKT1PKMHSD17B10ATMMEN1 | |
| Sulfadoxine SCHEMBL7167625 | 0.72 | ESR1 (0.71) | AKT1PKMHSD17B10ATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998966-B2 | Axl kinase inhibitors | SUPERGEN, INC. (US) | 2011-08-16 | — | — | US | claimed |
| EP-2139869-A2 | AXL KINASE INHIBITORS USEFUL FOR THE TREATMENT OF CANCER OR HYPERPROLIFERATIVE DISORDERS | SuperGen, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| US-20080293733-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-11-27 | — | — | US | claimed |
| WO-2008128072-A2 | AXL KINASE INHIBITORS USEFUL FOR THE TREATMENT OF CANCER OR HYPERPROLIFERATIVE DISORDERS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20110269772-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269772-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7998966-B2 | Axl kinase inhibitors | SUPERGEN, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998966-B2 | Axl kinase inhibitors | SUPERGEN, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998966-B2 | Axl kinase inhibitors | SUPERGEN, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080293733-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293733-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293733-A1 | AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008128072-A2 | AXL KINASE INHIBITORS USEFUL FOR THE TREATMENT OF CANCER OR HYPERPROLIFERATIVE DISORDERS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269772-A1 | AXL KINASE INHIBITORS | AXL, MERTK, ERBB2 | EGFR 62/4885AURKB 66/4885AKT1 65/4885 |
| US-20080293733-A1 | AXL KINASE INHIBITORS | AXL, MERTK, ERBB2 | EGFR 62/4885AURKB 66/4885AKT1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.